Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $200.00 and last traded at $200.00, with a volume of 35 shares traded. The stock had previously closed at $197.03.
UCB Stock Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average of $183.67 and a 200-day moving average of $169.35.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Legacy Tech Companies Reemerging as AI Leaders
- What is the Hang Seng index?
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
